According to the agreement, Seegene will develop and manufacture multiplex assays for Hologic’s next-gen molecular diagnostics platform; Hologic will receive worldwide commercialization rights to the assays. Financial terms of the deal were not disclosed.
Seegene touts its PCR technology as a tool to simultaneously identify and quantify multiple targets in a single fluorescence channel. The Seoul-based company says its technology can enable any real-time PCR instrument with double its multiplexing capacity without upgrading the instrument’s hardware.
“We are pleased to partner with Seegene and incorporate their innovative technologies with our system,” Hologic Diagnostics president Tom West said in prepared remarks. “Seegene’s multiplex reagents will enable simultaneous detection and quantification of various target genes, further broadening the menu of Hologic’s Panther Fusion system and strengthening its leadership position in the molecular diagnostic market.”
“Our agreement with Hologic represents another meaningful milestone to Seegene’s global expansion initiatives in the molecular diagnostics market,” Seegene founder & CEO Dr. Jong-Yoon Chun added. “We expect to accelerate technological standardization in the MDx market by building up capabilities of assay development applying on various platforms.”